Project Grant R01AR083960
- This federal Project Grant award for $243,950.00 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award supports a series of research aims to develop prognostic models for predicting the long-term course of atopic dermatitis (persistent disease and comorbidities) in diverse global settings, including cohorts from Uganda, Ecuador, and the United Kingdom....
- This $250,396 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to identify differences in DNA regulatory elements that control gene expression in skin cells from individuals of different ancestral backgrounds. The research team at the Icahn School of Medicine at Mount Sinai will utilize advanced genomic techniques, including...
- This federal Project Grant award, valued at $1,826,181.00 and effective from September 1, 2025 to August 31, 2028, was issued by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research grant program (CFDA 93.846). The grant aims to comprehensively understand the contribution of Langerhans cells, resident cells in the epidermis, to chronic itch associated with various skin and systemic diseases. The research...
- This Project Grant award, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to define and treat genetic abnormalities in overlapping rashes of psoriasis and atopic dermatitis (termed "PSO-AD"). The $628,968 award to the University of California, San Francisco will leverage innovative biomarker techniques, including spatial transcriptomics and...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $2,070,827 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846) to the Icahn School of Medicine at Mount Sinai. This grant aims to identify novel microbial factors that can enhance wound repair, a significant public health issue with over 100 million new acute skin wounds annually and substantial treatment costs exceeding $25 billion. The...
- This federal Project Grant award, valued at $1,901,310.00 and provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), supports research under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The research project aims to investigate how skin inflammation drives the development of psoriatic arthritis, a condition that affects up to one-third of individuals with psoriasis. The project will use a novel mouse model to study the...
- This Project Grant award, totaling $176,148.00 and effective from April 1, 2025 to March 31, 2030, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The funding supports a research project led by Dr. Maxime Kinet at the University of California, San Francisco (UCSF) that aims to elucidate the mechanisms by which PI16-expressing fibroblasts, a...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $343,904 to The Regents of the University of California, San Francisco to investigate transcriptional abnormalities in skin-resident T cells as potential biomarkers for atopic dermatitis in Asian and Hispanic genetic backgrounds. The research aims to validate an abnormal atopic T...
- This federal Project Grant award of $390,913 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support a mechanistic investigation into the role of the protein SERPINB3 in the pathogenesis of psoriasis. The research project, being conducted by Arizona State University, will explore the hypothesis that the misprocessing of SERPINB3 is the initiating factor in the...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research Federal Grant Program (CFDA 93.846), awarded a $726,898 Project Grant to Weill Medical College of Cornell University. The grant, awarded on August 1, 2025, will support a research project titled "Personalized Immunomonitoring to Understand Juvenile Dermatomyositis" with Principal Investigators Pascual, V. and Wilson, P. The project aims to...
This federal Project Grant award of $528,558.00 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The goal of the research project is to study the immune system mechanisms underlying treatment resistance and paradoxical inflammatory side effects in patients with atopic dermatitis who receive the antibody therapy dupilumab. The research will utilize human skin biopsies from dupilumab-treated patients to analyze the cellular and molecular features of the immune microenvironment in different disease states, including resolving, stable, and paradoxically flaring skin lesions. The project aims to address critical knowledge gaps and develop better treatment modalities for atopic dermatitis. The project period runs from September 1, 2025 through August 31, 2030 and will be conducted by the Icahn School of Medicine at Mount Sinai.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $528.6k | 8/8/25 |